4.6 Article

Performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification

Journal

PLOS ONE
Volume 16, Issue 1, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0243712

Keywords

-

Funding

  1. IPGG platform [ANR-10-EQPX-34]
  2. Carnot Pasteur Maladies Infectieuses program [ANR 11-CARN 017-01, ANR20-COVI-000]
  3. FONDS ESPCI

Ask authors/readers for more resources

This study introduces a portable device called COVIDISC for on-site COVID-19 testing, utilizing progress in isothermal amplification and paper microfluidics. The device extracts and amplifies SARS-CoV-2 RNA isothermally using RT-LAMP technology, with detection taking between 20 minutes to 1 hour, and showing no cross-reaction with eight major respiratory viruses currently circulating in Europe. The low cost and simplicity of the device are expected to facilitate widespread dissemination and help manage pandemics.
To respond to the urgent need for COVID-19 testing, countries perform nucleic acid amplification tests (NAAT) for the detection of SARS-CoV-2 in centralized laboratories. Real-time RT-PCR (Reverse transcription-Polymerase Chain Reaction), used to amplify and detect the viral RNA., is considered, as the current gold standard for diagnostics. It is an efficient process, but the complex engineering required for automated RNA extraction and temperature cycling makes it incompatible for use in point of care settings [1]. In the present work, by harnessing progress made in the past two decades in isothermal amplification and paper microfluidics, we created a portable test, in which SARS-CoV-2 RNA is extracted, amplified isothermally by RT-LAMP (Loop-mediated Isothermal Amplification), and detected using intercalating dyes or fluorescent probes. Depending on the viral load in the tested samples, the detection takes between twenty minutes and one hour. Using a set of 16 pools of nasopharyngal swab eluates, we estimated a limit of detection comparable to real-time RT-PCR (i.e. 1 genome copies per microliter of clinical sample) and no cross-reaction with eight major respiratory viruses currently circulating in Europe. We designed and fabricated an easy-to-use portable device called COVIDISC to carry out the test at the point of care. The low cost of the materials along with the absence of complex equipment will expedite the widespread dissemination of this device. What is proposed here is a new efficient tool to help managing the pandemics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available